ERBB2 L869R
| Gene | ERBB2 |
| Variant | missense |
| Amino Acid Change | L869R |
| DNA Change (Coding Nucleotide) | 2606T>G |
| Transcript ID (GRCh37/hg19) | ENST00000269571 |
| Codon | 869 |
| Exon | 21 |
| Genomic Coordinates (GRCh37/hg19) | 17:37881414-37881414 |
| COSMIC ID | 249793 |
| Germline/Somatic? | Somatic |
Pertinent Negative In
| Tumor Type | Primary Site | |
|---|---|---|
| Adenocarcinoma | Breast |
Interpretations
Sort by
Page
Show
Tier 2|
Variants
Primary Sites
Tumor Types
Interpretation
This mutation is recognized as gain of function mutation. Tumor with this mutation responds to neratinib, a type of TKI which is against HER2 and EGFR.
Last updated: 2018-12-13 21:07:39 UTC
Read More